Carfilzomib is a newer proteasome inhibitor that is now being used in the myeloma clinic. One meeting session compared three different uses of carfilzomib for newly diagnosed multiple myeloma patients:

Which one would offer the longer remissions?

 

KRD with transplant has shown some very good results as has KRD without transplant.  When I asked myeloma experts to share their top 5 abstracts, two of the four specialists chose Abstract 121.  This abstract is intended to answer the question in a head-to-head study as to which is best. 

 

The title of this abstract is “Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs Krd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-Kcd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM).”  

 

The median follow up of the comparison is only 20 months, so more time is required to determine if the results for overall survival.  The conclusions of the trial are as follows:

 

Longer follow-up will be interesting to show the long-term impact of stem cell transplant in the future.